Results 71 to 80 of about 4,828 (174)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) hospitalizations have increased since the 2014 guideline update recommended against the use of palivizumab for preterm infants born ≥29 0/7 weeks' gestational age (GA) without additional risk factors. A novel
Tianzhou Yu, William V. Padula, Leah Yieh, Cynthia L. Gong   +3 more
doaj   +1 more source

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan.
Naruhiko Ishiwada, Rina Akaishi, Yasuhiro Kobayashi, Kanae Togo, Naohiro Yonemoto, Moe Matsuo, Shinnosuke Kaneko, Amy W. Law, Kazumasa Kamei   +8 more
doaj   +1 more source

MODERN POTENTIALITIES OF IMMUNOPROPHYLAXIS OF SEVERE COURSE OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH THE CONSEQUENCES OF PERINATAL PATHOLOGY

Педиатрическая фармакология, 2011
To a risk group of a heavy course of the respiratory syncytial viral (RSV) infection could be ascribed preterm infants, born before the 35th week of gestation inclusive, as well as children under 2 years old with the bronchopulmonary dysplasia or ...
L.S. Namazova-Baranova, I.V. Davydova, T.V. Turti, I.A. Belyaeva, V.V. Altunin   +4 more
doaj  

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies

Clinical Epidemiology, 2014
Marie Linder,1 Camilla Byström,1 Helle Kieler,1 Gunnar Bergman,2 Ann Haerskjold3,4 1Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden; 2Stockholm-Uppsala Department of Pediatric Cardiology ...
Linder M, Byström C, Kieler H, Bergman G, Haerskjold A   +4 more
doaj  

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants. [PDF]

Cost Eff Resour Alloc
Rodriguez-Martinez CE, Ordonez J, Carbonell-Estrany X, Fullarton J, Keary I, Rodgers-Gray B, D'Apremont I, Noyola DE, Ribeiro PA, Stein RT, Vain N, Tarride JE, Paes B.   +12 more
europepmc   +1 more source

The Effectiveness of Respiratory Syncytial Virus Prophylaxis Programme using Palivizumab in Preterm Infants: <i>A single institute retrospective study</i>. [PDF]

Sultan Qaboos Univ Med J
Al Mandhari H, Al Kendi S, Al-Balushi N, Bintaqi A, Al Saadi A, Abdellatif M.   +5 more
europepmc   +1 more source

Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis. [PDF]

Lancet Reg Health Eur
Perramon-Malavez A, Chiaretti A, Coma E, Craiu M, Foster S, Leonard P, Marlow R, Thors V, Martínez-Marcos M, Mendioroz J, Vila J, Creus-Costa A, Prats C, Roland D, Soriano-Arandes A, Williams TC, Buonsenso D.   +16 more
europepmc   +1 more source

Recommendations on Respiratory Syncytial Virus (RSV) Immunization Strategies for Infants and Young Children in Countries with Year-Round RSV Activity. [PDF]

Vaccines (Basel)
Cheah FC, Khoo EJ, Ali A, Ismail Z, Awang RA, Ng DC, Chan PWK, Ahmad Kamar A, Chua XY, Sam JI, Abdul Manaf MR, Kassim A.   +11 more
europepmc   +1 more source

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants. [PDF]

J Pharm Technol
Phillips B, Jackson C, Phillips J.
europepmc   +1 more source

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants. [PDF]

Cureus
Chamarthi S, Gupta S, Chamarthi VS.
europepmc   +1 more source